Oncogenic Functions and Clinical Significance of Circular RNAs in Colorectal Cancer

Simple Summary Over the last few years, circular RNAs (circRNAs) are highly anticipated as new diagnostic and prognostic biomarkers. Our review aimed to present new data about circRNAs as targets in oncogenic axes to inhibit cancer activity. The review of circRNAs was made in the context of their oncogenic functions. Special attention was paid to circRNAs with clinical significance and to circRNAs with diagnostic and prognostic potential in colorectal cancer (CRC). Studies that evaluate the differential expression of circRNAs in the circulation between patients with CRC and healthy controls were considered. The review could be useful with its comprehensive information about known cicrRNAs with oncogenic function in CRC and with the questions it raises about the reliability of circRNAs as non-invasive biomarkers. Colorectal cancer (CRC) is ranked as the second most commonly diagnosed disease in females and the third in males worldwide. Therefore, the finding of new more reliable biomarkers for early diagnosis, for prediction of metastasis, and resistance to conventional therapies is an important challenge in overcoming the disease. The current review presents circular RNAs (circRNAs) with their unique features as potential prognostic and diagnostic biomarkers in CRC. The review highlights the mechanism of action and the role of circRNAs with oncogenic functions in the CRC as well as the association between their expression and clinicopathological characteristics of CRC patients. The comprehension of the role of oncogenic circRNAs in CRC pathogenesis is growing rapidly and the next step is using them as suitable new drug targets in the personalized treatment of CRC patients.

Automated summary

Recent studies have highlighted the potential of circRNAs as new diagnostic and prognostic biomarkers in colorectal cancer (CRC), with a focus on their clinical significance and diagnostic potential. The reliability of circRNAs as non-invasive biomarkers and the challenges of finding more reliable biomarkers for early diagnosis and predicting metastasis and resistance to therapies have been discussed. There is a growing understanding of the role of oncogenic circRNAs in CRC pathogenesis and the potential for using them as new drug targets in personalized treatment.